Tillotts Pharma AG
Tillotts Pharma AG, headquartered in Switzerland (CH), is a prominent player in the pharmaceutical industry, specialising in gastrointestinal therapies. Founded in 2000, the company has established itself as a leader in developing innovative treatments for conditions such as inflammatory bowel disease and irritable bowel syndrome. With a strong presence in Europe and expanding operations in other regions, Tillotts Pharma is renowned for its unique product offerings, including the well-regarded 5-ASA compound, which sets it apart in the market. The company’s commitment to research and development has led to significant milestones, enhancing its reputation for quality and efficacy. Recognised for its contributions to patient care, Tillotts Pharma AG continues to solidify its market position through strategic partnerships and a focus on unmet medical needs, making it a trusted name in gastrointestinal health.
DitchCarbon Score
How does Tillotts Pharma AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tillotts Pharma AG's score of 26 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tillotts Pharma AG's reported carbon emissions
Tillotts Pharma AG, headquartered in Switzerland (CH), currently does not have publicly available carbon emissions data or specific reduction targets. Without concrete figures or commitments, it is challenging to assess their climate impact or initiatives. However, the pharmaceutical industry is increasingly focusing on sustainability and reducing carbon footprints. Companies are encouraged to adopt science-based targets and engage in climate pledges to mitigate their environmental impact. As such, Tillotts Pharma AG may be exploring or implementing strategies to align with industry standards for climate action, although specific details are not provided.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tillotts Pharma AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
